Tumor growth decreases NK and B cells as well as common lymphoid progenitor.
BACKGROUND
It is well established that chronic tumor growth results in functional inactivation of T cells and NK cells. It is less clear, however, whether lymphopoeisis is affected by tumor growth.


RESULTS
In our efforts of analyzing the impact of tumor growth on NK cell development, we observed a major reduction of NK cell numbers in mice bearing multiple lineages of tumor cells. The decrease in NK cell numbers was not due to increased apoptosis or decreased proliferation in the NK compartment. In addition, transgenic expression of IL-15 also failed to rescue the defective production of NK cells. Our systematic characterization of lymphopoeisis in tumor-bearing mice indicated that the number of the common lymphoid progenitor was significantly reduced in tumor-bearing mice. The number of B cells also decreased substantially in tumor bearing mice.


CONCLUSIONS
Our data reveal a novel mechanism for tumor evasion of host immunity and suggest a new interpretation for the altered myeloid and lymphoid ratio in tumor bearing hosts.
Richards
John
J
Department of Pathology, Division of Cancer Immunology, The Ohio State University Medical Center and Comprehensive Cancer Center, Columbus, Ohio, United States of America.
McNally
Beth
B
Fang
Xianfeng
X
Caligiuri
Michael A
MA
Zheng
Pan
P
Liu
Yang
Y
D000818:Animals; D017209:Apoptosis; D001402:B-Lymphocytes / Q000166:cytology* / Q000276:immunology; D045744:Cell Line, Tumor; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D019409:Interleukin-15 / Q000378:metabolism; D007694:Killer Cells, Natural / Q000166:cytology* / Q000276:immunology; D054503:Lymphoid Progenitor Cells / Q000166:cytology* / Q000276:immunology; D038041:Lymphopoiesis; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000276:immunology*
D019409:Interleukin-15
Science. 1988 Jul 1;241(4861):58-62
2898810
Cancer Immunol Immunother. 2004 Feb;53(2):64-72
14593498
Cancer Immunol Immunother. 2006 Mar;55(3):237-45
16047143
Clin Dev Immunol. 2003 Jun-Dec;10(2-4):71-81
14768937
Proc Natl Acad Sci U S A. 1986 May;83(10):3427-31
2871552
Blood. 2000 Jun 1;95(11):3489-97
10828034
Cell. 1997 Nov 28;91(5):661-72
9393859
Eur J Immunol. 2001 Jun;31(6):1900-9
11433387
Cancer Immunol Immunother. 2002 Aug;51(6):293-8
12111117
J Exp Med. 1997 Nov 3;186(9):1609-14
9348320
Blood. 2003 Sep 15;102(6):2138-45
12750171
Blood. 2002 Nov 15;100(10):3633-8
12393617
Immunity. 2002 Oct;17(4):463-72
12387740
Nature. 2000 Mar 9;404(6774):193-7
10724173
Blood. 2000 Sep 1;96(5):1961-8
10961901
Exp Hematol. 1981 Aug;9(7):691-6
7318972
Immunity. 1998 Nov;9(5):669-76
9846488
J Exp Med. 2003 Apr 21;197(8):967-76
12695488
Blood. 1996 Sep 15;88(6):2279-87
8822949
Eur J Immunol. 2003 Jan;33(1):119-24
12594840
Blood. 2006 Jul 1;108(1):246-52
16556890
J Immunother. 2001 Nov-Dec;24(6):431-46
11759067
J Exp Med. 2001 Jan 15;193(2):219-31
11208862
J Exp Med. 2000 Mar 6;191(5):771-80
10704459
J Cell Mol Med. 2005 Oct-Dec;9(4):777-94
16364190
J Immunol. 2002 Oct 15;169(8):4153-60
12370344
Oncogene. 2002 May 13;21(21):3295-313
12032771
Oncogene. 2004 Sep 20;23(43):7188-98
15378079
J Exp Med. 1977 May 1;145(5):1411-6
859002
Blood. 1998 Nov 15;92(10):3647-57
9808558
J Clin Invest. 2002 Nov;110(10):1539-48
12438451
J Immunol. 1999 Sep 1;163(5):2648-56
10453005
J Exp Med. 1997 Feb 3;185(3):499-505
9053450